Related Experiment Video
Updated: Aug 22, 2025
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
Twist1 as a target for prevention of cutaneous squamous cell carcinoma
Tingzeng Wang1, Okkyung Rho1, Fernando Eguiarte-Solomon2
1Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Abstract:
Cutaneous squamous cell carcinoma (cSCC) represents an important clinical problem requiring novel approaches for both prevention and treatment. The transcription factor, Twist-related protein 1 (Twist1), has been identified as having a key mechanistic role in the development and progression of cSCC. Studies in relevant mouse models of cSCC have shown that Twist1 regulates epithelial-mesenchymal transition (EMT) and stemness driving progression and metastasis of cSCC. In addition, further research has shown that Twist1 regulates the balance between keratinocyte proliferation and differentiation and therefore impacts earlier stages of cSCC development. Through use of keratinocyte specific Twist1 knockout models, a role for this gene in keratinocyte stem cell homeostasis has been revealed. As a transcription factor, Twist1 regulates a large number of genes both in a positive, as well as a negative manner across several interdependent pathways. Studies in keratinocyte specific knockout models have shown that Twist1 upregulates the expression of genes involved in proliferation, stemness, and EMT while downregulating the expression of genes associated with differentiation. Furthermore, a number of compounds, including naturally occurring compounds, have been identified that target Twist1 and can block its effects in cancer cells and in keratinocytes in vivo. Collectively, the current understanding of Twist1 function in cSCC development and progression suggests that it represents a potential target for prevention and treatment of cSCC.
Insights
Twist-related protein 1 (Twist1) drives cutaneous squamous cell carcinoma (cSCC) development by regulating cell growth, stemness, and metastasis. Targeting Twist1 offers a promising strategy for cSCC prevention and treatment.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Cutaneous squamous cell carcinoma (cSCC) is a significant clinical challenge.
- The transcription factor Twist-related protein 1 (Twist1) plays a crucial role in cSCC development and progression.
Purpose of the Study:
- To elucidate the mechanistic role of Twist1 in cSCC development and progression.
- To explore Twist1 as a potential therapeutic target for cSCC.
Main Methods:
- Utilized keratinocyte-specific Twist1 knockout mouse models.
- Investigated Twist1's regulation of gene expression in keratinocytes.
- Examined Twist1's impact on epithelial-mesenchymal transition (EMT) and stemness.
Main Results:
- Twist1 regulates keratinocyte proliferation, differentiation, stemness, and EMT.
- Twist1 knockout models reveal its role in stem cell homeostasis.
- Twist1 upregulates proliferation, stemness, and EMT genes while downregulating differentiation genes.
Conclusions:
- Twist1 is a key regulator in cSCC development and progression.
- Targeting Twist1, potentially with natural compounds, shows promise for cSCC prevention and treatment.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Prevention
Some...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

